



PROGRAM

October 1–2, 2019

Miltenyi Biotec Campus

Bergisch Gladbach, Germany

DCID & Next Generation Vaccines Days

► miltenyibiotec.com



Miltenyi Biotec

Opening Remarks

Dear DCID & Next Generation Vaccines Days Attendees,

It is an exciting time for immunotherapy: advances in cell therapy, as well as the discovery and establishment of new therapeutic compounds enable us to define new and more effective combinations of treatments against cancer. Your efforts and ideas are being translated into hope for patients now and in the future.

Miltenyi Biotec cordially opens their doors to the Dendritic Cells Immunotherapy Days (DCID) & Next Generation Vaccines. This year's event will explore the current status of cancer vaccines from dendritic cell vaccination, to other cell therapy approaches, to new biotechnological and bioengineering developments, which contribute to generating cutting-edge tumor vaccines.

Today, clinicians and scientists are facing and overcoming challenges in protocol optimization, target selection, combination strategies, and regulatory environments, amongst many others. We at Miltenyi Biotec feel an obligation to invigorate and support this field. We are excited to host the second event of this kind to gather experts in the field of cellular therapy to network and to exchange ideas.

We hope you will be inspired by the work of your peers and take part in this active and incredible community, which stands as the leading force in cancer vaccine discovery.

Yours,
The Miltenyi Biotec Team

Tuesday, October 1, 2019

09:30 a.m. Registration

Session 1 Regulation and manufacturing of cancer vaccines

11:00 a.m. Critical aspects in delivery of monocyte-derived cellular therapies – preparation for large scale trials

John Campbell, Scottish National Blood Transfusion Service, Edinburgh, UK

Tba

Joachim Aerts, Erasmus MC, Rotterdam, Netherlands

Tba

01:00 p.m. Lunch

02:00 p.m. Miltenyi Biotec campus tour

Session 2 Advanced biomaterials for vaccine design

03:00 p.m. Development of personalized cancer nanovaccines against neoantigens

Li Tang, École polytechnique fédérale de Lausanne, Switzerland

Nanoparticle-based anticancer vaccine design with tumor-associated glycopeptides

Joseph Barchi, National Cancer Institute, Bethesda, Maryland, USA

Bioengineering lentivirus-induced dendritic cells for immune therapy of leukemia and HCMV and testing in fully humanized mouse systems

Renata Stripecke, Immunology Centre Hannover, Hannover Medical School, Germany

Tba

Matthias Bros, University Medical Center of the Johannes Gutenberg University Mainz, Germany

06:00 p.m. Shuttle to networking dinner

Wednesday, October 2, 2019

Session 3 Cancer vaccines and combination therapy

09:00 a.m. Tba

Evelien Smits, Ph.D., Center for Oncological Research, University of Antwerp, Belgium

Exploring the therapeutic potential of intratumoral myeloid dendritic cell therapy

Bart Neyns, Oncology Center, Universitair Ziekenhuis Brussel; Vrije Universiteit Brussel, Belgium

Accuracy of dendritic cell vaccines plus chemotherapy in the neoadjuvant scenario in breast cancer patients

Marta Santisteban Eslava, Clínica Universidad de Navarra, Spain

11:00 a.m. Break

Session 4 Advanced biomaterials for vaccine design

11:20 p.m. Nanovaccines remodel tumor immune microenvironment, sensitizing solid tumors to immune checkpoint therapy

Helena Florindo, University of Lisbon, Portugal

Gaining spatial control over innate immune activation by synthetic macromolecular conjugates of small molecule TLR7/8 agonists

Bruno de Geest, Cancer Research Institute Ghent, Belgium

Tba

01:00 p.m. Lunch

- Session 5** **Cancer vaccines and combination therapy**
- 02:00 p.m.** **Blood-derived dendritic cell vaccinations in castration-resistant prostate cancer**
Harm Westdorp, Radboud University Nijmegen, Netherlands
- Targeting MAPK pathways in natural DC subsets for next generation DC vaccine**
Andrew Jackson, Nottingham City Hospital, UK
- Tba**
Stuart Curbishley, Centre for Liver Research, University of Birmingham, UK
- 04:10 p.m.** **Closing remarks**



Miltenyi Biotec

Miltenyi Biotec GmbH

Friedrich-Ebert-Straße 68 | 51429 Bergisch Gladbach | Germany

Phone +49 2204 8306-0 | Fax +49 2204 85197

macs@miltenyibiotec.de | www.miltenyibiotec.com

Miltenyi Biotec provides products and services worldwide.

Visit www.miltenyibiotec.com/local to find your nearest Miltenyi Biotec contact.

The statements and other contributions presented at the meeting and the views expressed therein are those of the attending experts and do not necessarily represent the policy or opinion of Miltenyi Biotec or any institution the respective expert may be associated with. Neither Miltenyi Biotec nor any of its directors or employees give any representation or warranty as to the reliability, accuracy, or completeness of the content thereof. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. This notice must accompany any further distribution of this document. Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use. MACS and the MACS logo are registered trademarks or trademarks of Miltenyi Biotec GmbH and/or its affiliates in various countries worldwide. Copyright © 2019 Miltenyi Biotec GmbH and/or its affiliates. All rights reserved.